Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; A Single Arm Study.
Soltanzadeh S, Saeedian A, Ghalehtaki R, Ayati M, Nowroozi M, Haddad P, Sabet MS, Kheirolahi A.
Soltanzadeh S, et al.
Clin Genitourin Cancer. 2023 Feb;21(1):105.e1-105.e6. doi: 10.1016/j.clgc.2022.07.007. Epub 2022 Jul 19.
Clin Genitourin Cancer. 2023.
PMID: 35948483
Clinical Trial.
After maximal TURBT, 66Gy/33 daily fractions of radiation were administered with concurrent chemotherapy of cisplatin (35 mg/m(2)) and capecitabine (625 mg/m(2)). The primary endpoint was treatment tolerability, defined as receiving capecitabine+cisplatin combinatio …
After maximal TURBT, 66Gy/33 daily fractions of radiation were administered with concurrent chemotherapy of cisplatin (35 mg/m(2)) an …